Toujeo SoloStar FDA Approval History
FDA Approved: Yes (First approved February 25, 2015)
Brand name: Toujeo SoloStar
Generic name: insulin glargine [rDNA origin]
Dosage form: Injection
Previous Name: Toujeo
Company: Sanofi
Treatment for: Diabetes, Type 1, Diabetes, Type 2
Toujeo SoloStar (insulin glargine [rDNA origin] is a once-daily long-acting basal insulin used to improve glycemic control in adults with type 1 and type 2 diabetes.
Development timeline for Toujeo SoloStar
| Date | Article |
|---|---|
| Mar 27, 2018 | Approval FDA Approves Toujeo (insulin glargine) Max SoloStar |
| Feb 25, 2015 | Approval Sanofi Receives FDA Approval of Once-Daily Basal Insulin Toujeo |
| Jul 8, 2014 | FDA Accepts Sanofi's New Drug Application for Basal Insulin Toujeo |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
